Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $19,550.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.82, for a total transaction of $19,550.00. Following the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at $943,834.90. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Richard Nolan Townsend also recently made the following trade(s):

• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.10, for a total value of $40,500.00.
• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $10.65, for a total value of $53,250.00.

Lexeo Therapeutics Trading Down 0.7 %

LXEO traded down $0.05 during trading on Wednesday, reaching $7.64. The company had a trading volume of 5,966,935 shares, compared to its average volume of 244,379. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. Lexeo Therapeutics, Inc. has a 12-month low of $7.47 and a 12-month high of $22.33. The company has a market cap of $252.58 million and a price-to-earnings ratio of -0.52. The firm’s 50-day simple moving average is $9.24 and its 200 day simple moving average is $12.33.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). Equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -2.76 earnings per share for the current year.

Analyst Ratings Changes

LXEO has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Lexeo Therapeutics in a research note on Thursday, October 31st. Leerink Partners reduced their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Chardan Capital increased their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $22.43.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Lexeo Therapeutics by 107.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after acquiring an additional 33,013 shares during the period. Values First Advisors Inc. acquired a new position in Lexeo Therapeutics in the third quarter worth about $67,000. Rhumbline Advisers boosted its stake in Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after buying an additional 3,627 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Lexeo Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.